ESTROGEN RECEPTOR POSITIVE
Clinical trials for ESTROGEN RECEPTOR POSITIVE explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN RECEPTOR POSITIVE trials appear
Sign up with your email to follow new studies for ESTROGEN RECEPTOR POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Breast cancer study: does adding trastuzumab to Pre-Surgery chemo improve outcomes?
Disease control CompletedThis phase II trial studied 92 women with early-stage breast cancer to see how well chemotherapy (paclitaxel and cyclophosphamide) with or without trastuzumab works before surgery. The main goals were to check side effects and see if the tumor disappears completely by the time of…
Matched conditions: ESTROGEN RECEPTOR POSITIVE
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Major trial pits three chemo drugs against each other for advanced breast cancer
Disease control CompletedThis large phase III trial tests which of three chemotherapy drugs—paclitaxel, nab-paclitaxel, or ixabepilone—works best, with or without the targeted drug bevacizumab, for people with stage IIIC or IV breast cancer that has returned or spread. The study aims to find the most eff…
Matched conditions: ESTROGEN RECEPTOR POSITIVE
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immunotherapy-Chemo cocktail shows promise in tough breast cancer
Disease control CompletedThis phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy carboplatin could help people with HER2-negative metastatic breast cancer that has spread. The 12 participants had cancer cells in their blood and had already tried …
Matched conditions: ESTROGEN RECEPTOR POSITIVE
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo shows promise for hard-to-treat cancers
Disease control CompletedThis early-phase trial tested a new drug called ALRN-6924 combined with the chemotherapy paclitaxel in 28 adults with advanced solid tumors that had spread or couldn't be removed by surgery, including a type of breast cancer. The main goal was to find the safest dose and check fo…
Matched conditions: ESTROGEN RECEPTOR POSITIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC